Onco Decision Dx connects patients, physicians, health systems and commercial laboratories with the first and only clinically validated, FDA-cleared blood test for enumerating Circulating Tumor Cells (CTC's).
At Onco Decision Dx, we provide physicians with the ability to measure and monitor their patient’s state of cancer and response to treatment, and the ability to personalize the patient’s care needs. This level of precision medicine is captured through a non-invasive blood sample, where individual CTC’s are counted - a very precise, non-invasive and efficient alternative to tissue biopsy and imaging. For patients previously diagnosed with cancer, our tests offer a solution when a tissue biopsy is insufficient or not possible.
Using a patient’s own blood to extract CTC’s and certain biomarkers, healthcare providers are able to develop personalized treatment plans using the actionable molecular information derived from the patient’s blood sample.
Services provided by Onco Decision Dx are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Partnering with industry leaders and cancer centers, we continually advance toward evolutions in cancer diagnostics and monitoring.